Syndax Pharmaceuticals appoints Keith A. Katkin to board
Mr. Katkin most recently served as the President and Chief Executive Officer of Avanir Pharmaceuticals, a publicly traded biopharmaceutical company, from March 2007 through January 2016, leading the execution of the company’s sale to Otsuka Pharmaceutical Co., Ltd. in 2015.
Mr. Katkin joined Avanir in July 2005 as the Senior Vice President of Sales and Marketing and was responsible for developing and executing the corporate strategy that led to the approval of Nuedexta and the company’s commercial success.
Prior to joining Avanir, he served as the vice president, Commercial Development for Peninsula Pharmaceuticals, Inc., playing a key role in the concurrent initial public offering and sale of the company to Johnson and Johnson.
Additionally, Mr. Katkin’s employment experience includes leadership roles at InterMune, Amgen and Abbott Laboratories.
In his role as a Director of Syndax, he will serve on the Audit Committee and the Nominating and Corporate Governance Committee of the Board.
Mr. Katkin currently serves on the Board of Directors of Avanir Pharmaceuticals, Inc., MC10, Inc., Otic Pharma Ltd. (Chairman), Rigel Pharmaceuticals, Inc., and the Brain Injury Association of America.
Mr. Katkin has an M.B.A. from the Anderson School at UCLA and earned his B.S. in Business and Accounting from Indiana University. He is also a licensed Certified Public Accountant. ■
LATEST MOVES FROM Massachusetts
- Dunkin' Brands names Roland Smith to board
- Radius Health appoints Jesper Høiland as CEO
- Athenahealth announces CFO transition
- Analogic Corporation appoints Michael Bourque as CFO
- InVivo Therapeutics appoints Richard Toselli as CMO
More inside POST
Perrigo Q1 net income $72 million Earnings